Tango Therapeutics, Inc. Other Nonoperating Income (Expense)
Tango Therapeutics, Inc. (TNGX) reported Other Nonoperating Income (Expense) of $722.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-11
- Tango Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $722.00K, a 20.66% decline year-over-year.
- Tango Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $1.08M, a 0.47% increase year-over-year.
- Tango Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $1.38M, a 6.50% decline year-over-year.
- Tango Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was $705.00K, a 63.96% decline year-over-year.
- Tango Therapeutics, Inc. other nonoperating income (expense) for fiscal 2025 was $4.07M, a 46.54% decline from fiscal 2024.
- Tango Therapeutics, Inc. other nonoperating income (expense) for fiscal 2024 was $7.61M, a 28.05% increase from fiscal 2023.
- Tango Therapeutics, Inc. other nonoperating income (expense) for fiscal 2023 was $5.94M, a 298.12% increase from fiscal 2022.
- Tango Therapeutics, Inc. other nonoperating income (expense) for fiscal 2022 was $1.49M.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $722.00K 10-Q · filed 2026-08-11 | $1.80M 10-Q · filed 2026-08-11 | $3.18M derived: sum of 3 quarters · filed 2026-08-11 | $3.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.08M 10-Q · filed 2026-05-13 | $2.46M derived: sum of 2 quarters · filed 2026-05-13 | $3.16M derived: sum of 3 quarters · filed 2026-05-13 | $4.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.08M derived: sum of 2 quarters · filed 2026-03-05 | $3.00M derived: sum of 3 quarters · filed 2026-08-11 | $4.07M 10-K · filed 2026-03-05 |
| 2025-09-30 | $705.00K 10-Q · filed 2025-11-04 | $1.61M derived: sum of 2 quarters · filed 2026-08-11 | $2.69M 10-Q · filed 2025-11-04 | $4.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $910.00K 10-Q · filed 2026-08-11 | $1.98M 10-Q · filed 2026-08-11 | $3.46M derived: sum of 3 quarters · filed 2026-08-11 | $5.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.07M 10-Q · filed 2026-05-13 | $2.55M derived: sum of 2 quarters · filed 2026-05-13 | $4.51M derived: sum of 3 quarters · filed 2026-05-13 | $6.50M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.43M derived: sum of 2 quarters · filed 2026-03-05 | $5.43M derived: sum of 3 quarters · filed 2026-03-05 | $7.61M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.96M 10-Q · filed 2025-11-04 | $3.95M derived: sum of 2 quarters · filed 2025-11-04 | $6.13M 10-Q · filed 2025-11-04 | $8.20M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-05 | $4.18M 10-Q · filed 2025-08-05 | $6.24M derived: sum of 3 quarters · filed 2026-03-05 | $7.75M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $2.18M 10-Q · filed 2025-05-12 | $4.25M derived: sum of 2 quarters · filed 2026-03-05 | $5.76M derived: sum of 3 quarters · filed 2026-03-05 | $6.91M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.58M derived: sum of 2 quarters · filed 2026-03-05 | $4.73M derived: sum of 3 quarters · filed 2026-03-05 | $5.94M 10-K · filed 2026-03-05 |
| 2023-09-30 | $1.51M 10-Q · filed 2024-11-06 | $2.67M derived: sum of 2 quarters · filed 2024-11-06 | $3.88M 10-Q · filed 2024-11-06 | $4.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.15M 10-Q · filed 2024-08-07 | $2.37M 10-Q · filed 2024-08-07 | $3.33M derived: sum of 3 quarters · filed 2025-02-27 | $3.86M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.22M 10-Q · filed 2024-05-08 | $2.18M derived: sum of 2 quarters · filed 2025-02-27 | $2.71M derived: sum of 3 quarters · filed 2025-02-27 | $2.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $967.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.49M derived: sum of 2 quarters · filed 2025-02-27 | $1.54M derived: sum of 3 quarters · filed 2025-02-27 | $1.49M 10-K · filed 2025-02-27 |
| 2022-09-30 | $523.00K 10-Q · filed 2023-11-08 | $573.00K derived: sum of 2 quarters · filed 2023-11-08 | $526.00K 10-Q · filed 2023-11-08 | $445.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $50.00K 10-Q · filed 2023-08-07 | $3.00K 10-Q · filed 2023-08-07 | -$78.00K derived: sum of 3 quarters · filed 2023-08-07 | -$128.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$47.00K 10-Q · filed 2023-05-09 | -$128.00K derived: sum of 2 quarters · filed 2023-05-09 | -$178.00K derived: sum of 3 quarters · filed 2023-05-09 | -$240.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$131.00K derived: sum of 2 quarters · filed 2023-03-27 | -$193.00K derived: sum of 3 quarters · filed 2023-03-27 | -$248.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | -$50.00K 10-Q · filed 2022-11-10 | -$112.00K derived: sum of 2 quarters · filed 2022-11-10 | -$167.00K 10-Q · filed 2022-11-10 | -$165.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$62.00K 10-Q · filed 2022-08-10 | -$117.00K 10-Q · filed 2022-08-10 | -$115.00K derived: sum of 3 quarters · filed 2022-08-10 | -$111.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$55.00K 10-Q · filed 2022-05-11 | -$53.00K derived: sum of 2 quarters · filed 2022-05-11 | -$49.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $6.00K derived: sum of 2 quarters · filed 2022-03-28 | $120.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $4.00K 10-Q · filed 2021-11-09 | $118.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |